Lower limits of CRRT dose-intensity: what does the evidence support? - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Exploring the Minimum CRRT Dose-Intensity: Evidence-Based Insights

  • By

  • Nuttha Lumlertgul

  • Sean M. Bagshaw

  • September 28, 2026

Share

Clinical Scorecard: Exploring the Minimum CRRT Dose-Intensity: Evidence-Based Insights

At a Glance

CategoryDetail
ConditionContinuous Renal Replacement Therapy (CRRT)
Key MechanismsAssociation between CRRT dose-intensity and mortality rates.
Target PopulationPatients requiring renal replacement therapy.
Care SettingCritical care settings.

Key Highlights

  • Lower CRRT dose-intensity thresholds are associated with increased mortality.
  • Cox hazard ratios indicate significant risk at lower dose thresholds.
  • Exploratory findings suggest a minimum effective dose may exist.
  • Ongoing trials are investigating the lower limit of CRRT dose-intensity.

Guideline-Based Recommendations

Diagnosis

  • Assess renal function and indications for CRRT initiation.

Management

  • Monitor and adjust CRRT dose-intensity based on patient response.

Monitoring & Follow-up

  • Regularly evaluate patient outcomes and adjust treatment protocols.

Risks

  • Consider the risk of mortality associated with low CRRT dose-intensity.

Patient & Prescribing Data

Patients in critical care requiring renal support.

Dose-intensity should be carefully calibrated to avoid increased mortality risk.

Clinical Best Practices

  • Utilize multivariable Cox models for assessing treatment effects.
  • Ensure clarity in reporting and interpreting dose-intensity data.
  • Engage in ongoing research to refine CRRT dosing guidelines.

Related Resources & Content

Original Source(s)

Lower limits of CRRT dose-intensity: what does the evidence support?

  • by Nuttha Lumlertgul, Sean M. Bagshaw

  • September 28, 2026

Related Content

ACS report: Lung cancer deaths plunge as survival doubles

Lung cancer deaths fell by more than half among US males as smoking declined, earlier-stage diagnoses increased, and 5-year relative survival doubled.

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

Alcohol use may have declined since 2022

National data show declines in any and heavy alcohol use since 2022.